Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
See the metal guts of a satellite in this wild X-ray view | Space photo of the day for Dec. 4, 2025 - 2Warming winters lead to more nitrate pollution in the drinking water near farms
- 3Outside Lovers' Decision: Favored Climbing Rucksacks
- 4Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- 5Savvy Watches: Which One Is Appropriate for You?
- 5 Great High-Mileage Electric Vehicles Of 2024
- Shelby County deputies charged with assault, placed on leave
- Select Your Cherished Fish
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- Two UN peacekeepers killed in explosion in Lebanon
- New research reveals urban raccoons across the US show early signs of domestication
- New India programme supports tribal families hosting tourists
- The Best Portable Applications for Emotional wellness and Prosperity
- NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
